Text size: Menopausal Hormone Therapy: Preventive Medication
Release Date: October 2012
This topic is in the process of being updated. Please go to the Update in Progress section to see the latest documents available.
Recommendation Summary
Summary of Recommendations and Evidence
| Population | Recommendation | Grade (What's This?) |
|---|---|---|
| Postmenopausal Women | The USPSTF recommends against the use of combined estrogen and progestin for the prevention of chronic conditions in postmenopausal women. | The USPSTF recommends against the service. There is moderate or high certainty that the service has no net benefit or that the harms outweigh the benefits |
| Postmenopausal Women, Who Have Had a Hysterectomy | The USPSTF recommends against the use of estrogen for the prevention of chronic conditions in postmenopausal women who have had a hysterectomy. | The USPSTF recommends against the service. There is moderate or high certainty that the service has no net benefit or that the harms outweigh the benefits |
This recommendation applies only to postmenopausal women who are considering hormone therapy for the primary prevention of chronic medical conditions. This is not a recommendation about the use of hormone therapy to treat menopausal symptoms, such as hot flashes or vaginal dryness; the USPSTF did not review the evidence related to this possible indication because it falls outside of the mission and scope of the USPSTF. This recommendation also does not apply to women younger than 50 years who have had surgical menopause.
Internet Citation: Final Update Summary: Menopausal Hormone Therapy: Preventive Medication. U.S. Preventive Services Task Force. September 2016.
https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/menopausal-hormone-therapy-preventive-medication
